t-Darpp is frequently over-expressed in human adenocarcinomas of the esophagus, prostate, stomach, colon and breast [23] and over-expression of t-Darpp is sufficient to confer resistance to trastuzumab in HER2+ breast cancer [17, 18, 24]. Here, ERBB2 is linked to breast carcinoma.